MarginsXMarginsX
Home › Markets › Health Care › AZN

AstraZeneca PLC (AZN)

AZN trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$184.02
-0.23% on the day
Market cap
$285.4B
Mega cap
Revenue · 2025
$58.7B
+8.6% on 2024
Net income · 2025
$10.2B
17.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerAZN on NYSE
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited Kingdom
IPO year2026
SEC CIK0000901832
SEC industry codePharmaceutical Preparations
Incorporated inUnited Kingdom

Financials · 2025

LineValue
Revenue$58.7B
Net income$10.2B
Operating income$13.7B
Net margin17.4%
Operating margin23.4%
Revenue growth+8.6%
Cash$5.7B
Total assets$114.1B
P/E (computed)27.9×
P/S (computed)4.9×

Warning signs

Cash runway
Cash-flow positive
$5.7B cash at December 31, 2025
Share count, 1 year
See the dilution note
Going-concern doubt
No
20-F filed February 24, 2026
Insider net buying, 12 months
-$2.2M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-02-24
Cash and burn$5.7B cash; operating cash flow $3.6B a quarter.Report 2025-12-31
Shares outstanding1,550,907,927 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 years1; latest 1-for-2 on 2026-02-02Source 2026-02-02
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
Delisting25-NSE filed25-NSE 2026-05-28
AuditorPricewaterhouseCoopers LLP, London, United KingdomPCAOB Form AP 2026-03-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $3K, sold $2.2M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$58.7B$10.2B$14.6B$5.7B$29.6B$58.7B20-F 2026-02-24
FY 2024
2024-12-31
$54.1B$7.0B$11.9B$5.5B$30.3B$54.1B20-F 2026-02-24
FY 2023
2023-12-31
$45.8B$6.0B$10.3B$5.8B$28.6B$45.8B20-F 2026-02-24
FY 2022
2022-12-31
$44.4B$3.3B$9.8B$6.2B$29.2B$44.4B20-F 2025-02-18
FY 2021
2021-12-31
$37.4B$112.0M$6.0B$6.3B$30.8B$37.4B20-F 2024-02-20
FY 2020
2020-12-31
$26.6B$3.2B$4.8B$7.8B$20.4B$26.6B20-F 2023-02-21
FY 2019
2019-12-31
$24.4B$1.3B$3.0B$5.4B$18.2B$24.4B20-F 2022-02-22
FY 2018
2018-12-31
$22.1B$2.2B$2.6B$4.8B$19.1B$22.1B20-F 2021-02-16

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B22026-02-27
Latest annual report20-F2026-02-24
Latest quarterly / interim
BAXFENDY RECOMMENDED FOR APPROVAL IN THE EU
6-K2026-11-16

Source: SEC EDGAR submissions feed, 1,006 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.1%
1 month+18.4%
3 months+17.3%
Year to date+0.3%
1 year+4.1%
From 52-week high-11.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NVSNovartis AG$160.20-0.19%$305.7B
MRKMerck & Company Inc. Common Stock (new)$144.46-2.23%$356.1B
ABTAbbott Laboratories$107.45-0.99%$186.1B
NVONovo Nordisk A/S$41.60-0.07%$184.2B
PFEPfizer Inc.$28.86-0.10%$164.5B
ABBVAbbVie Inc.$294.55-0.16%$520.7B
VRTXVertex Pharmaceuticals Incorporated$537.79-0.15%$136.4B
BMYBristol-Myers Squibb Company$62.93-0.79%$128.6B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier